Shares of SBP GROUP (01177) climbed more than 5% during the morning session. At the time of writing, the stock was up 5.39% to HK$5.08, with a turnover of HK$239 million.

Expanding a Strategic Partnership

On July 8, SBP GROUP announced that its subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd., is deepening its exclusive strategic collaboration with GlaxoSmithKline PLC (GSK), originally established in May 2026. This move aims to broaden access to two innovative respiratory drugs for more patients in China. This development represents a significant step forward in the strategic partnership between the group and GSK, marking an expansion of their collaborative focus from liver diseases into the respiratory disease sector.

Terms of the New Agreement

Under the terms of the agreement, the group has secured the commercial rights in mainland China for two of GSK's innovative respiratory medicines: fluticasone furoate/umeclidinium/vilanterol (brand name: Trelegy Ellipta) and umeclidinium/vilanterol (brand name: Anoro Ellipta). SBP GROUP will be responsible for the importation, distribution, hospital access, and promotional activities related to these products in mainland China. All sales revenue generated from these products will be recognized as revenue for the Zhengda Tianqing subsidiary.